NOVARTIS sheds light and pioneers in research and activities to raise awareness on Sickle Cell Disease
- Sickle Cell Disease is one of the most common chronic blood disorders in the world1. Globally around 300,000 babies are born with the disease annually while 300 million people carry the trait.4,9 Gulf is a region with one of the highest prevalence rates of Sickle Cell Disease among Middle Eastern ancestry marking Saudi, Oman, and Bahrain as the countries with the highest rates respectively.17
- Sickle cell pain crises or VOCs are considered the clinical hallmark of the disease, and are triggered, in part, by multicellular interactions that form clusters of cells, which can block or reduce the blood flow to organs.2 Sickle cell pain crises can be frequent and sudden, and are associated with an increased risk of life-threatening complications.13,14
- A reduction in VOCs is therefore the focus of scientific innovation in this disease area, and a key measure of its success.
- Sharing inspirational stories of Sickle Cell patients from around the world lends a positive light to those affected by the disease and reaffirms that these patients overcome many hurdles to be productive in the society.
- June 19th has been designated as World Sickle Cell Day and in 2020 will run under the campaign NOTALONEINSICKLECELL, (notaloneinsickcell.com), and rethinksicklecelldisease.com